Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 5/20 | 0.45 |
| ▸ | ATP4B | P51164 | 5/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481410 | 1.00 | ATP4A (0.45) | ATP4AATP4BAHRCNR1PDGFRB | |
| SCHEMBL1481743 | 0.92 | TLR8 (0.43) | ATP4AATP4BAHRTLR8LMNA | |
| SCHEMBL1481741 | 0.92 | TLR8 (0.43) | ATP4AATP4BAHRTLR8LMNA | |
| SCHEMBL1480840 | 0.90 | FFAR1 (0.42) | ATP4AATP4BCNR1PPARA | |
| SCHEMBL1480837 | 0.90 | FFAR1 (0.42) | ATP4AATP4BCNR1PPARA | |
| SCHEMBL1481899 | 0.89 | TLR8 (0.43) | AHRCNR1TLR8LMNAMAPT | |
| SCHEMBL1481901 | 0.89 | TLR8 (0.43) | AHRCNR1TLR8LMNAMAPT | |
| SCHEMBL1480972 | 0.86 | TLR8 (0.42) | TLR8LMNAMAPTTP53SMN1; SMN2 | |
| SCHEMBL1480970 | 0.86 | TLR8 (0.42) | TLR8LMNAMAPTTP53SMN1; SMN2 | |
| SCHEMBL1481578 | 0.84 | PPARA (0.41) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | ATP4A 2140/4885ATP4B 2971/4885AHR 1771/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | ATP4A 2140/4885ATP4B 2971/4885AHR 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.